Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy

Cancer

Volumn 118, Issue 16, 2012, Pages 4053-4062

  Zafarana, Gaetano ^a   Ishkanian, Adrian S ^a,b,c   Malloff, Chad A ^d   Locke, Jennifer A ^a,b,c   Sykes, Jenna ^c   Thoms, John ^a,b,c   Lam, Wan L ^d   Squire, Jeremy A ^e   Yoshimoto, Maisa ^e   Ramnarine, Varune Rohan ^a,b,c   Meng, Alice ^a,c   Ahmed, Omar ^a,c   Jurisca, Igor ^a,b,c   Milosevic, Michael ^a,b,c   Pintilie, Melania ^a,b,c   Van Der Kwast, Theo ^a,b   Bristow, Robert G ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^e QUEEN S UNIVERSITY   (Canada)

Author keywords

c MYC; comparative genomic hybridization; genetic instability; Gleason score; prostate cancer; prostate specific antigen; radiotherapy; T category

Indexed keywords

ARTICLE; CANCER PROGNOSIS; CANCER RELAPSE; COHORT ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER ALTERATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE LOSS; GENE MUTATION; GENETIC GAIN; GENOMIC INSTABILITY; HUMAN; HUMAN TISSUE; IMAGE GUIDED RADIOTHERAPY; MAJOR CLINICAL STUDY; MALE; ONCOGENE C MYC; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PTEN GENE; RISK ASSESSMENT;

ADULT; DNA COPY NUMBER VARIATIONS; GENES, MYC; GENOMIC INSTABILITY; HUMANS; LOSS OF HETEROZYGOSITY; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RADIOTHERAPY, IMAGE-GUIDED; RECURRENCE;

EID: 84864716473     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26729     Document Type: Article

References (34)

1. D'Amico AV, Whittington R, Malkowicz SB, et al. Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy Gleason score, and clinical T-stage. Int J Radiat Oncol Biol Phys. 1999; 45: 1227-1233.
2. Nichol AM, Warde P, Bristow RG,. Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: clinical and translational issues. Cancer. 2005; 104: 891-905.
3. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010; 8: 162-200.
4. Roach M III, Waldman F, Pollack A,. Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer. 2009; 115: 3112-3120.
5. Lapointe J, Li C, Giacomini CP, et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res. 2007; 67: 8504-8510.
6. van Duin M, van Marion R, Vissers K, et al. High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer. Genes Chromosomes Cancer. 2005; 44: 438-449.
7. Sato H, Minei S, Hachiya T, Yoshida T, Takimoto Y,. Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients. Int J Urol. 2006; 13: 761-766.
8. Yang G, Timme TL, Frolov A, Wheeler TM, Thompson TC,. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer. 2005; 103: 1186-1194.
9. Hawksworth D, Ravindranath L, Chen Y, et al. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer Prostatic Dis. 2010; 13: 311-315.
10. Ishkanian AS, Mallof CA, Ho J, et al. High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate. 2009; 69: 1091-1100.
11. Jenkins RB, Qian J, Lieber MM, Bostwick DG,. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res. 1997; 57: 524-531.
12. Kim JH, Dhanasekaran SM, Mehra R, et al. Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res. 2007; 67: 8229-8239.
13. Luoto KR, Meng AX, Wasylishen AR, et al. Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair. Cancer Res. 2010; 70: 8748-8759.
14. Ishkanian AS, Zafarana G, Thoms J, Bristow RG,. Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer. Acta Oncol. 2010; 49: 888-894.
15. Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle. 2011; 10: 1192-1199.
16. Evangelisti C, Ricci F, Tazzari P, et al. Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. J Cell Physiol. 2011; 226: 822-831.
17. Pattje WJ, Schuuring E, Mastik MF, et al. The phosphatase and tensin homologue deleted on chromosome 10 mediates radiosensitivity in head and neck cancer. Br J Cancer. 2010; 102: 1778-1785.
18. Deutsch E, Soria JC, Armand JP,. New concepts for phase I trials: evaluating new drugs combined with radiation therapy. Nat Clin Pract Oncol. 2005; 2: 456-465.
19. Roach M III, Weinberg V, Nash M, Sandler HM, McLaughlin PW, Kattan MW,. Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials. J Urol. 2006; 176: S16-S20.
20. Khojasteh M, Lam WL, Ward RK, MacAulay C,. A stepwise framework for the normalization of array CGH data. BMC Bioinformatic. 2005; 6: 274.
21. Shah SP, Xuan X, DeLeeuw RJ, et al. Integrating copy number polymorphisms into array CGH analysis using a robust HMM. Bioinformatics. 2006; 22: e431-e439.
22. Chi B, DeLeeuw RJ, Coe BP, MacAulay C, Lam WL,. SeeGH-a software tool for visualization of whole genome array comparative genomic hybridization data. BMC Bioinformatics. 2004; 5: 13.
23. Chi B, deLeeuw RJ, Coe BP, Ng RT, MacAulay C, Lam WL,. MD-SeeGH: a platform for integrative analysis of multi-dimensional genomic data. BMC Bioinformatics. 2008; 9: 243.
24. Joshua AM, Shen E, Yoshimoto M, et al. Topographical analysis of telomere length and correlation with genomic instability in whole mount prostatectomies. Prostate. 2011; 71: 778-790.
25. Yoshimoto M, Cunha IW, Coudry RA, et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer. 2007; 97: 678-685.
26. Bedolla R, Prihoda TJ, Kreisberg JI, et al. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res. 2007; 13: 3860-3867.
27. Wolfer A, Ramaswamy S,. Prognostic signatures, cancer metastasis and MYC. Cell Cycle. 2010; 9: 3639.
28. Anai S, Shiverick K, Medrano T, et al. Downregulation of BCL-2 induces downregulation of carbonic anhydrase IX, vascular endothelial growth factor, and pAkt and induces radiation sensitization. Urology. 2007; 70: 832-837.
29. Cao C, Subhawong T, Albert JM, et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res. 2006; 66: 10040-10047.
30. Fraser M, Harding SM, Zhao H, Coackley C, Durocher D, Bristow RG,. MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. Cell Cycle. 2011; 10: 2218-2232.
31. Mendes-Pereira AM, Martin SA, Brough R, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med. 2009; 1: 315-322.
32. Gupta A, Lotan Y, Ashfaq R, et al. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol. 2009; 55: 1124-1133.
33. Cuddihy AR, Bristow RG,. The p53 protein family and radiation sensitivity: yes or no? Cancer Metastasis Rev. 2004; 23: 237-257.
34. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007; 26: 4596-4599.